Innovation across neurological oligonucleotide therapeutics is accelerating. With 73 new assets added to the neurological landscape in 2026 and growing investment across both established and emerging modalities, the competitive environment continues to evolve rapidly.
Join Isabella Rios and Matty Slingsby as they examine the latest developments across the neurological oligonucleotide market, including advances in preclinical and clinical pipelines, emerging delivery strategies, and the technologies helping developers overcome long-standing challenges such as blood-brain barrier penetration. Recent growth in siRNA programmes highlights increasing confidence in next-generation approaches, while established modalities continue to expand across a growing number of neurological indications.
Attendees will gain a data-driven view of the current landscape, key companies to watch, and the trends expected to shape future development and commercial opportunity.
Key Highlights:
- Review the latest neurological oligonucleotide pipeline developments
- Understand why siRNA is experiencing significant growth across the market
- Explore emerging approaches to blood-brain barrier delivery
- Identify the therapies, technologies, and modalities gaining momentum
- Discover future opportunities shaping neurological drug development
Why Attend?
- Stay ahead of rapidly evolving market and pipeline activity
- Benchmark innovation across leading oligonucleotide developers
- Identify emerging technologies and delivery platforms to watch
- Gain competitive intelligence to support R&D and business strategy
Register now for an informative session.
Webinar Leaders
Isabella Rios
Researcher at Beacon
Matty Slingsby
Commercial Manager at Beacon
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
